STOCK TITAN

Medigus Ltd. American Depositary Share - MDGS STOCK NEWS

Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.

Medigus Ltd. (NASDAQ: MDGS) is an innovative medical device company renowned for its groundbreaking endoscopic procedures and devices. The company has developed a comprehensive endoscopic system designed for the intraluminal treatment of Gastroesophageal Reflux Disease (GERD), a prevalent chronic condition in the Western world. The centerpiece of Medigus's offering is the SRS system, which integrates a miniaturized video camera, surgical stapler, and ultrasonic sights for precise alignment into a single, flexible endoscope. This unique system allows gastroenterologists and surgeons to perform endoluminal partial anterior fundoplications, thereby eliminating the need for traditional open or laparoscopic surgery, significantly advancing the clinical management of GERD.

Alongside its flagship SRS system, Medigus also designs and manufactures bespoke endoscopy systems for partner companies, leveraging its proprietary technology to meet diverse clinical needs. This dual focus on innovation in GERD treatment and custom endoscopic solutions underscores Medigus's commitment to advancing medical care through minimally invasive techniques.

Based in Israel, Medigus's recent initiatives include strategic partnerships and collaborations to expand the reach and application of their technologies. The company's financial health is bolstered by these partnerships, alongside a strong pipeline of ongoing projects aimed at enhancing patient outcomes and broadening the scope of endoscopic treatments.

For the latest updates, news, and detailed financial information, stakeholders can contact: Tali Dinar, Chief Financial Officer, at ir@medigus.com, or Michal Efraty, Investor Relations, at michal@efraty.com.

Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) announced the appointment of Yovav Sameah as the new CEO of its subsidiary, ScoutCam Inc.. Sameah succeeds Dr. Yaron Silberman, who is stepping down to explore new opportunities. With extensive experience in management and a background in leading global tech firms, Sameah aims to transition ScoutCam from an R&D to a fully commercialized entity. Prof. Benad Goldwasser, ScoutCam's Executive Chairman, highlighted Sameah's ability to drive sales and navigate the company's growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
management
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) announced its subsidiary, Smart Repair Pro, received regulatory approvals to launch sales on Amazon.de in Germany, the second-largest Amazon marketplace. CEO Victor Hachmon noted this expansion aligns with their strategy to grow revenue and reach more consumers. The companies utilize AI and machine learning for market analysis and plan to enhance their product offerings. This expansion is expected to contribute positively to Medigus' future revenue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) successfully completed an $8.5 million follow-on offering, facilitated by Aegis Capital Corp. as the sole bookrunner. The funds raised will support Medigus' focus on medical devices and internet technologies, including its innovative surgical technology for treating GERD and miniaturized imaging equipment through its subsidiary Scoutcam. The offering aims to enhance Medigus' capabilities in both medical and digital sectors, reflecting the company's ambition for growth and innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
none
Rhea-AI Summary

Medigus Ltd. (MDGS) has successfully closed an underwritten public offering of 3,258,438 American Depositary Shares (ADSs) at a price of $2.60 each, raising approximately $8.5 million before costs. The company plans to utilize the net proceeds for working capital and general corporate purposes. There is a 15% over-allotment option available to the underwriter, which could increase total proceeds to around $9.7 million. The offering was made under an effective registration statement previously filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
-
Rhea-AI Summary

Medigus Ltd. announced a public offering of 3,258,438 American Depositary Shares (ADSs), priced at $2.60 per ADS, aiming to raise approximately $8.5 million before costs. The funds will be directed towards working capital and general corporate purposes. The offering is scheduled to close around March 1, 2021, pending customary conditions, with a potential additional gross proceeds of $9.7 million if the underwriter's over-allotment option is fully exercised. Aegis Capital Corp. serves as the bookrunner.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9%
Tags
-
Rhea-AI Summary

Medigus Ltd. (NASDAQ: MDGS) announced an intention to offer American Depositary Shares (ADSs) in an underwritten public offering. The company plans to grant the underwriter a 15% option for over-allotments, exercisable for 45 days post-offering. Proceeds will be allocated for working capital and corporate purposes. The offering depends on market conditions, and there's no guarantee regarding completion or terms. Aegis Capital Corp. serves as the sole bookrunner. This follows an effective registration statement with the SEC from May 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9%
Tags
Rhea-AI Summary

Medigus Ltd. (NASDAQ:MDGS) announced an exclusive licensing agreement between its subsidiary Eventer Technologies Ltd. and Screenz Cross Media Ltd., focusing on the virtual conference market. Eventer will invest $1.5 million for adapting Screenz's technology, predicting substantial growth due to the COVID-19 pandemic. The global virtual events market was valued at $77.98 billion in 2019, expected to grow at a 23.2% CAGR through 2027. Adaptation of technology is anticipated to complete in the second half of 2021, with Screenz entitled to 8% of revenue from the product.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (NASDAQ:MDGS) has announced the formation of a joint venture, NewCo, for developing urban and logistics electric vehicles aimed at improving last-mile delivery solutions. This venture includes notable partners Amir Zaid and Weijian Zhou, founders of EMuze. Medigus plans to invest up to $1.35 million to gain a potential 50.1% ownership in NewCo based on achieving specific milestones, starting with an initial investment of $250,000.

The joint venture aims to create EVs that can operate a full working day on a single charge.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) announced the appointment of Mori Arkin to the board of its subsidiary, ScoutCam Inc. (OTCQB: SCTC). Arkin, who previously invested $2 million in ScoutCam, replaces Dr. Irit Yaniv on the board, reflecting his confidence in the company’s potential beyond medical visualization. His involvement is anticipated to enhance ScoutCam's business opportunities in various sectors, including maintenance and predictive technologies. Arkin's background includes founding and growing Arkin Holdings, with a significant portfolio in healthcare and pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
management
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) has announced the development of a robotic wireless charging pad for electric vehicles through its new subsidiary, Charging Robotics Ltd. Initial testing will occur in collaboration with a university in Israel. The autonomous system aims to provide on-demand charging anywhere, utilizing state-of-the-art Wireless Power Transfer (WPT) technology. Once fully developed, it will enable seamless charging of vehicles, enhancing convenience for electric vehicle users.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
none

FAQ

What is the current stock price of Medigus Ltd. American Depositary Share (MDGS)?

The current stock price of Medigus Ltd. American Depositary Share (MDGS) is $2.36 as of June 11, 2024.

What is the market cap of Medigus Ltd. American Depositary Share (MDGS)?

The market cap of Medigus Ltd. American Depositary Share (MDGS) is approximately 4.5M.

What does Medigus Ltd. specialize in?

Medigus Ltd. specializes in innovative endoscopic procedures and devices, particularly for the treatment of GERD.

What is the SRS system?

The SRS system is an endoscopic solution that combines a miniaturized camera, surgical stapler, and ultrasonic sights to treat GERD without open or laparoscopic surgery.

How does the SRS system benefit GERD patients?

The SRS system allows for a minimally invasive procedure, reducing the need for more invasive surgeries and potentially improving recovery times.

Does Medigus Ltd. collaborate with other companies?

Yes, Medigus designs and manufactures endoscopy systems for partner companies using its proprietary technologies.

Where is Medigus Ltd. based?

Medigus Ltd. is based in Israel.

Who can I contact for investor relations at Medigus?

For investor relations, you can contact Michal Efraty at michal@efraty.com.

What is the primary medical condition that Medigus's technology addresses?

Medigus's technology primarily addresses Gastroesophageal Reflux Disease (GERD).

How does the SRS system work?

The SRS system uses a flexible endoscope with a built-in camera, stapler, and ultrasonic guide to perform partial anterior fundoplication endoluminally.

What are the recent initiatives of Medigus Ltd.?

Recent initiatives include strategic partnerships and ongoing projects to enhance their technology's reach and applications.

How can I get the latest news about Medigus Ltd.?

You can get the latest news by contacting their Chief Financial Officer Tali Dinar or Investor Relations Michal Efraty, or visiting their official communications.

Medigus Ltd. American Depositary Share

Nasdaq:MDGS

MDGS Rankings

MDGS Stock Data

4.47M
28.42M
0.29%
0.22%
Medical Devices
Healthcare
Link
United States of America
Tel Aviv